Monday, May 23, 2005

End of the Road for Crestor?

In a study published in Circulation, the incidence of adverse events with rosuvastatin (Crestor) was 2 times higher than simvastatin (Zocor), and 6.8 times higher than atorvastatin (Lipitor).

In the big scheme of things, this translates to 6 per million deaths with Crestor, 3 per million for Zocor, and 2 per million for Lipitor. Not that common.

Still, do you really want to use a drug that has a higher mortality than the medications in the same group? Probably not.

Suddenly, Consumer Reports "Best Buy Drug" reviews seem a bit more scientific. Lipitor was their top choice for those who needed to reduce the LDL cholesterol by more than 40%.

Source:
Reuters, Circulation - 05/05

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.